Alevazol

Drug overview for ALEVAZOL (clotrimazole):

Generic name: CLOTRIMAZOLE (kloe-TRIM-a-zole)
Drug class: Topical Antifungals
Therapeutic class: Dermatological

Clotrimazole, an imidazole derivative, is a synthetic azole antifungal agent.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for ALEVAZOL (clotrimazole) have been approved by the FDA:

Indications:
Cutaneous candidiasis
Diaper rash
Tinea corporis
Tinea cruris
Tinea pedis
Tinea versicolor

Professional Synonyms:
Corporeal ringworm
Cutaneous candidosis
Cutaneous moniliasis
Dermatomycosis pedis
Dhobie itch
Diaper dermatitis
Eczema marginatum
Jock itch
Pityriasis versicolor
Tinea circinata
Tinea furfuracea
Tinea glabrosa
Tinea inguinalis
Tinea of the foot

Moderate List
No disease contraindications

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Abnormal desquamation Anaphylaxis Angioedema Blistering skin Dermatitis due to topical drug Dyspnea Edema Erythema Hypersensitivity drug reaction Hypotension Pruritus of skin Skin irritation Skin rash Stinging of skin Syncope Urticaria

The following precautions are available for ALEVAZOL (clotrimazole):

Pediatric
Pregnant
Lactation
Geriatric

Safety and efficacy of clotrimazole lozenges have not been established in children <3 years of age. Safety and efficacy of prophylactic therapy with clotrimazole lozenges have not been established in children. Clotrimazole topical cream or solution is not recommended for self-medication in children <3 years of age.

Clotrimazole vaginal cream is not recommended for self-medication in children <12 years of age. Preparations containing clotrimazole in fixed combination with betamethasone dipropionate are not recommended for use in children <17 years of age or for diaper dermatitis.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

There are no adequate and controlled studies of clotrimazole lozenges in pregnant women; the drug should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. In clinical trials, use of intravaginal clotrimazole in pregnant women in the second and third trimester was not associated with adverse effects; there are no adequate and well-controlled studies in pregnant women in the first trimester. . In animal reproductive studies, clotrimazole demonstrated embryotoxic effects, but was not teratogenic when given in doses significantly higher than the recommended human dose.

It is not known whether clotrimazole is excreted in human milk, caution should be exercised when the drug is used in nursing woman.

There were an insufficient number of patients >=65 years of age in clinical studies of clotrimazole lozenges to determine whether geriatric patients respond differently from younger patients; other reported experience did not find any differences in response between these patients.

Cutaneous candidiasis
B37.2	Candidiasis of skin and nail
Diaper rash
L22	Diaper dermatitis
Tinea corporis
B35.4	Tinea corporis
Tinea cruris
B35.6	Tinea cruris
Tinea pedis
B35.3	Tinea pedis
Tinea versicolor
B36.0	Pityriasis versicolor